HOTLINE: Effective January 2, 2020

New Test Available Now | **3002257** | **CV2.1 Screen by IFA with Reflex to Titer, CSF** | **CV2.1 CSF**

Methodology: Semi-Quantitative Indirect Fluorescent Antibody
Performed: Thu
Reported: 1-8 days

Specimen Required: Collect: CSF.
Specimen Preparation: Transfer 0.5 mL CSF to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Storage/Transport Temperature: Refrigerated.
Unacceptable Conditions: Hemolyzed, contaminated, or severely lipemic specimens.
Stability (collection to initiation of testing): Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month

Reference Interval: Less than 1:1

Interpretive Data: CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma.

See Compliance Statement D: www.aruplab.com/CS

Note: If CV2.1 Antibody IgG Screen by IFA, CSF is positive, then CV2.1 Antibody IgG Titer, CSF will be added. Additional charges apply.

CPT Code(s): 86255; if reflexed, add 86256

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.